Theralase Technologies has completed a brokered private placement, raising C$3.56 million by issuing 14.8 million units at C$0.24 each. The funds will support toxicology studies and clinical development of its cancer and antiviral drugs, including Rutherrin and Ruvidar, targeting cancers and herpes simplex virus. The company plans to advance regulatory filings and marketing approvals in Canada and the US. Insider participation and agent compensation were disclosed, with final listing approvals pending from the TSX Venture Exchange.
The iShares 20+ Year Treasury Bond ETF (TLT) has lost more than 40% of its value since its August 2020 peak, even after accounting for monthly distributions. This decline highlights the risks of holding long-duration bond funds, which have no maturit...
Options traders have been buying bullish calls on the iShares 20+ Year Treasury Bond ETF (TLT) throughout the summer, signaling expectations of a rally in long-duration bonds despite rising yields. On Tuesday, over 175,000 calls were purchased compar...
